JPWO2022136370A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022136370A5 JPWO2022136370A5 JP2023538702A JP2023538702A JPWO2022136370A5 JP WO2022136370 A5 JPWO2022136370 A5 JP WO2022136370A5 JP 2023538702 A JP2023538702 A JP 2023538702A JP 2023538702 A JP2023538702 A JP 2023538702A JP WO2022136370 A5 JPWO2022136370 A5 JP WO2022136370A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- grna
- present
- fused
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 87
- 108020005004 Guide RNA Proteins 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 230000003612 virological effect Effects 0.000 claims description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000032258 transport Effects 0.000 claims description 9
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 claims description 6
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims description 6
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 claims description 6
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 241000192031 Ruminococcus Species 0.000 claims description 5
- 238000010353 genetic engineering Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000025721 COVID-19 Diseases 0.000 claims description 3
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 claims description 3
- 108090000994 Catalytic RNA Proteins 0.000 claims description 3
- 102000053642 Catalytic RNA Human genes 0.000 claims description 3
- 241000711573 Coronaviridae Species 0.000 claims description 3
- 208000001490 Dengue Diseases 0.000 claims description 3
- 206010012310 Dengue fever Diseases 0.000 claims description 3
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 3
- 208000005176 Hepatitis C Diseases 0.000 claims description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 3
- 201000005505 Measles Diseases 0.000 claims description 3
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 3
- 208000003152 Yellow Fever Diseases 0.000 claims description 3
- 208000001455 Zika Virus Infection Diseases 0.000 claims description 3
- 201000004296 Zika fever Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 208000025729 dengue disease Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 241001493065 dsRNA viruses Species 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 208000037797 influenza A Diseases 0.000 claims description 3
- 230000030147 nuclear export Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 2
- 108091035707 Consensus sequence Proteins 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000001124 posttranscriptional effect Effects 0.000 claims 1
- 241000192026 Ruminococcus flavefaciens Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LULU102326 | 2020-12-22 | ||
| LU102326 | 2020-12-22 | ||
| PCT/EP2021/086992 WO2022136370A1 (en) | 2020-12-22 | 2021-12-21 | Application of crispr/cas13 for therapy of rna virus and/or bacterium induced diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024500932A JP2024500932A (ja) | 2024-01-10 |
| JPWO2022136370A5 true JPWO2022136370A5 (https=) | 2025-01-31 |
| JP2024500932A5 JP2024500932A5 (https=) | 2025-01-31 |
Family
ID=74626052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538702A Pending JP2024500932A (ja) | 2020-12-22 | 2021-12-21 | Ｒｎａウイルスおよび／または細菌誘発性の疾患の治療に対するｃｒｉｓｐｒ／ｃａｓ１３の応用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240041990A1 (https=) |
| EP (1) | EP4267736A1 (https=) |
| JP (1) | JP2024500932A (https=) |
| CN (1) | CN116917478A (https=) |
| CA (1) | CA3203046A1 (https=) |
| WO (1) | WO2022136370A1 (https=) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| EP1025217B1 (en) | 1997-10-24 | 2006-10-04 | Invitrogen Corporation | Recombinational cloning using nucleic acids having recombination sites |
| US10056224B2 (en) | 2015-08-10 | 2018-08-21 | Kla-Tencor Corporation | Method and system for edge-of-wafer inspection and review |
| CA3028158A1 (en) * | 2016-06-17 | 2017-12-21 | The Broad Institute, Inc. | Type vi crispr orthologs and systems |
| CN111108220B (zh) * | 2017-03-15 | 2024-11-19 | 博德研究所 | 用于病毒检测的基于crispr效应系统的诊断 |
| AU2018234825B2 (en) * | 2017-03-15 | 2020-12-17 | Massachusetts Institute Of Technology | Novel CAS13B orthologues CRISPR enzymes and systems |
| US11168322B2 (en) * | 2017-06-30 | 2021-11-09 | Arbor Biotechnologies, Inc. | CRISPR RNA targeting enzymes and systems and uses thereof |
| WO2019010422A1 (en) * | 2017-07-07 | 2019-01-10 | The Broad Institute, Inc. | ANTIVIRAL THERAPY BASED ON THE CRISPR SYSTEM |
| WO2019018423A1 (en) * | 2017-07-17 | 2019-01-24 | The Broad Institute, Inc. | NEW TYPE VI CRISPR ORTHOLOGISTS AND ASSOCIATED SYSTEMS |
| US10476825B2 (en) * | 2017-08-22 | 2019-11-12 | Salk Institue for Biological Studies | RNA targeting methods and compositions |
| CN107939288B (zh) | 2017-11-14 | 2019-04-02 | 中国科学院地质与地球物理研究所 | 一种非旋转套的防转装置以及旋转导向装置 |
| CN113348245A (zh) * | 2018-07-31 | 2021-09-03 | 博德研究所 | 新型crispr酶和系统 |
| US12258594B2 (en) * | 2018-12-05 | 2025-03-25 | The Broad Institute, Inc. | Cas proteins with reduced immunogenicity and methods of screening thereof |
| CN110656123B (zh) * | 2019-10-12 | 2021-07-13 | 中国农业大学 | 基于CRISPR-Cas13d系统的sgRNA高效作用靶点的筛选方法及应用 |
-
2021
- 2021-12-21 WO PCT/EP2021/086992 patent/WO2022136370A1/en not_active Ceased
- 2021-12-21 JP JP2023538702A patent/JP2024500932A/ja active Pending
- 2021-12-21 CN CN202180094344.1A patent/CN116917478A/zh active Pending
- 2021-12-21 EP EP21843704.4A patent/EP4267736A1/en active Pending
- 2021-12-21 CA CA3203046A patent/CA3203046A1/en active Pending
- 2021-12-21 US US18/268,948 patent/US20240041990A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12016908B2 (en) | Compositions and methods for treating hemoglobinopathies | |
| BRPI9905902B8 (pt) | "molécula polinucleotídica isolada, plasmídeo, e método para produzir um vírus prrs norte-americano" | |
| US20240200042A1 (en) | Limited self-replicating mrna molecular system, producing method and use | |
| AU2024261906A1 (en) | Modified guide rna | |
| EP4172329A2 (en) | Compositions for genome editing and methods of use thereof | |
| CN119421716A (zh) | 用于环状rna亲和纯化的组合物和方法 | |
| BR0012938A (pt) | Método para a produzir um vìrus recombinante de caxumba, vìrus recombinante de caxumba, composição, método para imunizar um indivìduo, molécula de ácido nucleico, plasmìdeo, célula hospedeira, composição farmacêutica, e sequência de nucleotìdeos | |
| CA3187036A1 (en) | Methods of identifying and characterizing anelloviruses and uses thereof | |
| JP2018148865A (ja) | ボルナウイルスベクター及びその利用 | |
| WO2022219607A1 (en) | Codon-optimized nucleotide sequences encoding a coronavirus spike protein and uses thereof | |
| CA3206361A1 (en) | In vitro assembly of anellovirus capsids enclosing rna | |
| JPWO2022136370A5 (https=) | ||
| CN114457077A (zh) | 靶向新型冠状病毒rna及其反义链utr的脱氧核酶及其应用 | |
| US20230140799A1 (en) | DECOY TRANSCRIPTS FOR TREATMENT OF ssRNA VIRAL INFECTION | |
| US20240277834A1 (en) | Nucleic acid molecules | |
| JPWO2022204093A5 (https=) | ||
| WO2024188312A1 (en) | Compositions and methods for enhanced protein expression | |
| US20250375538A1 (en) | COMPOSITIONS AND METHODS FOR IMPROVED mRNA PRODUCTION | |
| CN120005875B9 (zh) | 一种优化的polyA序列结构及其应用 | |
| US20240209035A1 (en) | Polynucleotides capable of enhanced protein expression and uses thereof | |
| CN120548366A (zh) | 疫苗 | |
| CN116790636A (zh) | 一种编码表达新城疫病毒抗原的信使核酸分子 | |
| US9068160B2 (en) | Methods of producing an antisense viral particle population | |
| CN120888576A (zh) | 用于使用CRISPR/Cas12b进行基因编辑的工程化mRNA | |
| WO2025087417A1 (zh) | 一种高效低脱靶的基因编辑工具 |